Johnson & Johnson Innovative Medicine at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Johnson & Johnson Innovative Medicine brings 2 presentations to PEGS Europe 2026 in Lisbon. Its program centres on multispecific T cell engagers paired with co-stimulation to treat cancer, and on emerging modalities in antibody engineering.

OrganizationPEGS Europe 2026 Attendance
jnj.com
Large pharma
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with antibody and multispecific medicines in oncology and immunology.
Talk
Wed Nov 18
2:05pm–2:35pm
Multispecific T Cell Engagers and Co-Stimulation Combinations for the Treatment of Cancer Patients
Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Panel
Wed Nov 18
4:10pm–4:50pm
Emerging Modalities and the Future of Antibody Engineering
Plenary · with Stanford University, University of Stuttgart, Cullinan Therapeutics
Protein and antibody engineering

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Johnson & Johnson Innovative Medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction